Form 483

Samsung Bioepis Co., Ltd. Form 483, 2023-09-15

FDA issued a Form 483 to Samsung Bioepis Co., Ltd. on 2023-09-15 with 2 public-safe observations.

483· Form 483 issuedHuman Drugs2 observations

Samsung Bioepis Co., Ltd. · Yeonsu, Korea (the Republic of) · Issued September 15, 2023

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

15 Sep 2023
21 CFR 312.50

General responsibilities of sponsors

Cited by Scott N Lim

15 Sep 2023
21 CFR 600.80(c)(1)(iii)

Reporting Requirements - submission of reports

Cited by Scott N Lim

Inspected site

SBSamsung Bioepis Co., Ltd.Yeonsu, Korea (the Republic of)

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 312.50Cited across public-safe Form 483 observations1x
21 CFR 600.80(c)(1)(iii)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 2 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere